<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul D Miller, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2874590"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoporosis is a common disease that is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture, particularly at the spine, hip, wrist, humerus, and pelvis [<a href="#rid1">1</a>]. It is difficult to diagnose osteoporosis in the setting of chronic kidney disease (CKD). This is particularly relevant for the aging population, where fragility fractures, reduced glomerular filtration rate (GFR), and low bone mineral density (BMD) are more prevalent. </p><p>There are multiple reasons why this differentiation is important, not the least of which is that management of osteoporosis differs vastly from treatment of other bone diseases in patients with CKD.</p><p>This topic will review the diagnosis and evaluation of osteoporosis in patients with CKD. The management of osteoporosis in CKD, as well as the pathogenesis, diagnosis, and management of other aspects or mineral and bone disorders (MBD) in patients with CKD are reviewed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/114322.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H4023030496"><span class="h1">CKD-MBD DEFINITION</span><span class="headingEndMark"> — </span>Changes in mineral metabolism and bone structure develop early in the course of chronic kidney disease (CKD) and worsen with progressive loss of kidney function. CKD-MBD (mineral and bone disorder) includes [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and vitamin D metabolism</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in bone turnover, mineralization, volume, linear growth, or strength</p><p class="bulletIndent1">and/or</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular or other soft tissue calcification</p><p></p><p>The more severe forms of CKD-MBD define the systemic nature of phosphorus and bone metabolism in progressive stages of CKD in order to link these changes to the vascular calcification that is the major cause of mortality in CKD. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p>Renal osteodystrophy is now a term confined to the spectrum of bone histomorphometry in CKD. Renal osteodystrophy includes hyperparathyroid-mediated, high-turnover bone disease or osteitis fibrosa cystica; adynamic bone disease; osteomalacia; and mixed uremic osteodystrophy. (See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>.)</p><p>It is difficult to diagnose osteoporosis in the setting of CKD-MBD. Patients with CKD may have osteoporosis either before or after developing kidney disease. Osteoporosis, a term that includes major alterations in bone quality, is probably a universal feature accompanying bone disease in all forms of renal bone disease  (<a class="graphic graphic_table graphicRef115571" href="/z/d/graphic/115571.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H931356"><span class="h1">FRACTURE RISK IN CHRONIC KIDNEY DISEASE</span></p><p class="headingAnchor" id="H709745"><span class="h2">Magnitude of the problem</span><span class="headingEndMark"> — </span>End-stage chronic kidney disease (CKD) is associated with an increased risk of fragility (low trauma) fractures [<a href="#rid3">3-5</a>]. The risk of fracture-related mortality increases with the severity of CKD [<a href="#rid3">3,6</a>].</p><p>In most [<a href="#rid5">5,7-16</a>], but not all [<a href="#rid17">17</a>], studies, more moderate degrees of renal insufficiency have also been associated with an increased fracture risk. In a systematic review and meta-analysis of studies evaluating fracture risk in adults with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m<sup>2</sup>, there was a significant increase in hip (relative risk [RR] 2.36, 95% CI 1.64-3.39) and nonvertebral (RR 1.47, 95% CI 1.15-1.88) fractures compared with eGFR ≥60 mL/min/1.73 m<sup>2</sup>, and fracture risk increased with decreasing eGFR [<a href="#rid18">18</a>]. In a large health care database study from Canada, decreasing eGFR was associated with an increase in the three-year cumulative incidence of fracture (hip, forearm, pelvis, proximal humerus) in females and males [<a href="#rid13">13</a>]. In females &gt;65 years of age, the incidence of fracture was 4.3, 5.8, 6.5, 7.8, and 8.6 percent for eGFR thresholds of ≥60, 45 to 59, 30 to 44, 15 to 29, and under 15 mL/min/1.73 m<sup>2</sup>. The incidence for males was 1.6, 2, 2.7, 3.8, and 5 percent, respectively. </p><p>The exact mechanism for this greater fracture risk in CKD is not clearly established, but there are biological changes in bone metabolism that render the skeleton in patients with progressive CKD (glomerular filtration rate [GFR] stages G3 to G5  (<a class="graphic graphic_table graphicRef70597" href="/z/d/graphic/70597.html" rel="external">table 2</a>)) more fragile. These changes, including phosphorus retention, secondary hyperparathyroidism, chronic acid loads, elevated fibroblast growth factor 23 (FGF23), or sclerostin overproduction, may contribute independently or collectively to the increased fracture risk that is seen in GFR stages G3 to G5 [<a href="#rid2">2,19-22</a>]. In addition, the greater risk of falls in this population with sarcopenia and frailty may also contribute to the greater fracture risk [<a href="#rid7">7</a>]. Other risk factors include glucocorticoid use, hypogonadism, hyperprolactinemia, poor nutrition, vitamin D deficiency, and inactivity [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H709752"><span class="h2">Assessment of fracture risk</span><span class="headingEndMark"> — </span>The assessment of fracture risk includes evaluation of clinical risk factors for fracture  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 3</a>), and, in most patients, measurement of bone mineral density (BMD) using dual-energy x-ray absorptiometry (DXA). (See <a class="local">'Bone mineral density: DXA'</a> below.)</p><p class="headingAnchor" id="H836266"><span class="h3">Fracture risk assessment tool</span><span class="headingEndMark"> — </span>In 2008, a World Health Organization (WHO) task force introduced a Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=13914" target="_blank">FRAX</a>), which estimates the 10-year probability of hip fracture and major osteoporotic fracture (hip, clinical spine, proximal humerus, or forearm) for untreated patients between ages 40 and 90 years using easily obtainable clinical risk factors for fracture  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 3</a>) and femoral neck BMD (g/cm<sup>2</sup>, using DXA), when available. This fracture risk assessment tool is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'</a>.)</p><p>FRAX does not include any adjustment of risk according to GFR. Although GFR (usually eGFR) was measured in some of the nine population studies used to construct the FRAX model, the sample size was not statistically powerful enough to validate the independent contribution of reduced GFR on fracture risk. In subsequent studies, FRAX was able to predict fracture in patients with CKD, the majority of whom had CKD stages G3a and G3b [<a href="#rid24">24,25</a>].</p><p>In clinical practice, FRAX may be applied to patients with CKD. Just as one may need to incorporate falls or frequency of falls (which were also not captured in FRAX) into a clinical judgment when utilizing FRAX, the clinician should also consider adjusting the absolute fracture risk to a higher level in patients with eGFR stages G3b to G5  (<a class="graphic graphic_table graphicRef70597" href="/z/d/graphic/70597.html" rel="external">table 2</a>) [<a href="#rid8">8,9,26-28</a>].</p><p class="headingAnchor" id="H836136"><span class="h3">Bone mineral density: DXA</span><span class="headingEndMark"> — </span>For patients with CKD, eGFR ≥30 mL/min/1.73 m<sup>2</sup>, and risk factors for fracture, BMD (dual-energy x-ray absorptiometry [DXA]) testing may be used to assess fracture risk. Although BMD testing is not routinely performed to assess fracture risk in patients with CKD and eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, it may be obtained in selected patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup> who have fragility fracture and no evidence of CKD-MBD (mineral and bone disorder), including renal osteodystrophy, particularly when osteoporosis therapy is being considered [<a href="#rid29">29</a>]. In these selected patients, measurement of BMD (hip and lumbar spine) at baseline and two years after osteoporosis therapy may also be helpful for monitoring response to therapy. (See  <a class="medical medical_review" href="/z/d/html/114322.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Management", section on 'Monitoring therapy'</a>.)</p><p>These suggestions are largely consistent with 2017 KDIGO guidelines (Kidney Disease: Improving Global Outcomes) and the 2021 CKD-MBD working group consensus statement from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) [<a href="#rid29">29,30</a>] and are based on observational studies described below.</p><p>Measurement of BMD by DXA is routinely used to diagnose osteoporosis and assess fracture risk in the general population. Many studies in the general population have demonstrated that low BMD is associated with an increased risk of fracture. Although BMD is also lower in patients with CKD who fracture, it is unclear if BMD by DXA can be used to predict fracture in patients with the most advanced CKD  (<a class="graphic graphic_table graphicRef115571" href="/z/d/graphic/115571.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]. Prospective studies in patients with end-stage CKD (particularly, G5D) are required to address this question. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Bone mineral density'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predialysis CKD</strong> – In cross-sectional studies, BMD by DXA has been shown to be lower in patients with predialysis CKD who fracture compared with those who do not [<a href="#rid31">31-33</a>]. In one study, for every standard deviation decrease in lumbar spine, total hip, femoral neck, and ultradistal radius BMD by DXA, there was a significant increase in the risk of fracture (odds ratios [ORs] 1.93, 1.65, 1.86, and 2.29, respectively) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis dependent</strong> – BMD is also lower in dialysis-dependent patients who fracture, as illustrated by the findings of a meta-analysis of six cross-sectional studies, which included 683 patients on dialysis [<a href="#rid35">35</a>]. Compared with patients without fracture, patients with fracture had significantly lower BMD at the lumbar spine (mean difference -0.44, 95% CI -0.8 to -0.08) and radial sites (one-third radius; mean difference -0.75, 95% CI -1.38 to -0.12), but not at the femoral neck (-0.5, 95% CI -1.08 to 0.08).</p><p></p><p class="bulletIndent1">In a subsequent study of Japanese dialysis patients, low hip BMD (DXA) was predictive of any type of incident fracture when the parathyroid hormone (PTH) was below the median value (204 pg/mL). However, the relationship between hip BMD and fracture was not significant if the PTH was above 204 pg/mL [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">In patients with advanced CKD and elevated PTH levels, the bone density is lost primarily from the cortical bone, and it may be increased in the cancellous bone. Bone density (DXA) in the cortical bone of the radius or hip is generally lower compared with the normal reference range, but the spine bone density (cancellous bone) may be within the normal range [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">DXA is unable to predict the type of bone lesion in dialysis-dependent patients [<a href="#rid26">26,38,39</a>]. The quantitative bone histomorphometric classification of renal bone diseases (eg, renal osteodystrophy) includes a heterogeneous group of bone diseases, all of which may have low T-scores and fragility fractures [<a href="#rid40">40,41</a>]. In addition, the interpretation of DXA may be confounded by the presence of extraosseous calcification and focal areas of osteosclerosis, which may lead to artifactual increase in BMD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limitations of DXA</strong> –<strong> </strong>Although DXA is the most commonly used technique to assess BMD in patients with and without CKD, it has some limitations. DXA measures areal BMD, rather than volumetric BMD. In addition, it cannot distinguish between cortical and cancellous bone, and it cannot assess bone microarchitecture or bone turnover. Thus, new technologies (high resolution microcomputed tomography [microCT] and micromagnetic resonance imaging [microMRI], hip structural analysis, finite element analysis) have been developed that allow noninvasive, three-dimensional evaluation of bone microarchitecture. There are few data evaluating these techniques in patients with CKD [<a href="#rid42">42</a>], and they are not available in most clinical settings. (see  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'New and emerging technologies'</a>)</p><p></p><p class="headingAnchor" id="H931363"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>In the general adult population, the clinical diagnosis of osteoporosis is made in one of two ways: the presence of a low trauma fracture independent of the prevailing bone mineral density (BMD) or, in the absence of a preexisting fracture, a certain level of BMD defined in standard deviation score terms, the T-score  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 4</a>). Many studies have demonstrated that low BMD measured by dual-energy x-ray absorptiometry (DXA) at any skeletal site (spine, hip, or forearm) can predict osteoporotic (fragility) fracture. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Fracture prediction'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>eGFR ≥30 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – In patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m<sup>2</sup>, the World Health Organization (WHO) criteria for BMD (T-score 2.5 standard deviations or more below the young adult mean BMD)  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 4</a>) or the presence of a fragility fracture may be used for the diagnosis of osteoporosis, assuming that there are no accompanying biochemical abnormalities (eg, hyperparathyroidism, hyperphosphatemia) that indicate the possible coexistence of renal osteodystrophy or CKD-MBD (mineral bone disorder). (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>eGFR &lt;30 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – In patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, who have low BMD T-scores, or history of fragility fracture, bone physiology is more complex and features of CKD-MBD may predominate. In this setting, a diagnosis of osteoporosis can only be made by excluding CKD-MBD, including renal osteodystrophy. (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p></p><p>The diagnosis of bone disease in patients with CKD (particularly with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>) can be challenging. In the aging population, fragility fractures, reduced glomerular filtration rate (GFR), and low BMD are common. An older patient with CKD and low BMD and/or a fragility fracture may have osteoporosis or another bone and mineral disorder related to CKD (eg, hyperparathyroidism, adynamic bone disease, osteomalacia) [<a href="#rid43">43,44</a>]. Furthermore, osteoporosis frequently coexists with CKD-MBD. There is uncertainty related to the applicability of the established WHO classification of BMD (DXA) according to T-score thresholds  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 4</a>). The WHO thresholds were chosen based upon fracture risk in postmenopausal White women [<a href="#rid45">45</a>]. Similar diagnostic threshold values for men are less well defined, although for any given BMD, the age-adjusted fracture risk is similar in males and females [<a href="#rid46">46</a>].</p><p>None of these populations specifically included individuals with CKD. However, the population used to establish the WHO criteria included many older individuals, who also may have had age-related reductions in GFR [<a href="#rid45">45</a>]. The disorders in bone metabolism due to kidney disease are less common with eGFR above 30 mL/min/1.73 m<sup>2</sup> [<a href="#rid2">2,41,47</a>]. Thus, based upon this evidence in the general population of postmenopausal women and aging men and upon clinical expertise, there has been some agreement that DXA has the same value for patients with eGFR ≥30 mL/min/1.73 m<sup>2</sup> as it has for patients without CKD [<a href="#rid23">23,26</a>].</p><p>In patients with more severe CKD (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>), the disorders in bone metabolism due to kidney disease are more prevalent and profound, such that the occurrence of a fragility fracture or WHO BMD criteria cannot be used for the diagnosis of osteoporosis [<a href="#rid29">29,43,48</a>]. There are few data to support a specific approach to the diagnosis of osteoporosis in G4 or G5 CKD.</p><p class="headingAnchor" id="H711196"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H764816315"><span class="h2">Osteoporosis versus CKD-MBD</span><span class="headingEndMark"> — </span>In patients with an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m<sup>2</sup> and low bone mineral density (BMD) (dual-energy x-ray absorptiometry [DXA] T-score ≤-2.5) and/or fragility fracture, the goal of the evaluation is to distinguish osteoporosis from other elements of chronic kidney disease-mineral and bone disorder (CKD-MBD), including renal osteodystrophy  (<a class="graphic graphic_table graphicRef115571" href="/z/d/graphic/115571.html" rel="external">table 1</a>).</p><p>The exclusion of renal adynamic bone disease is most important [<a href="#rid49">49-54</a>]. Adynamic bone disease is characterized by low osteoblastic activity and bone formation rates. One may not want to employ pharmacologic agents approved for the treatment of osteoporosis whose mechanism of action is to lower bone turnover when no bone turnover is evident. This concept is most important in light of the data linking low bone turnover to increased vascular calcification in CKD [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/91082.html" rel="external">"Adynamic bone disease associated with chronic kidney disease", section on 'Vascular calcification'</a>.)</p><p class="headingAnchor" id="H2896849228"><span class="h2">Laboratory assessment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>eGFR 30 to 60 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – For patients with eGFR ≥30 but &lt;60 mL/min/1.73 m<sup>2</sup> with a history of a fragility fracture and/or low BMD (DXA T-score ≤-2.5), we initially measure serum:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Calcium</p><p class="bulletIndent2"><span class="glyph">•</span>Phosphorus</p><p class="bulletIndent2"><span class="glyph">•</span>Parathyroid hormone (PTH)</p><p class="bulletIndent2"><span class="glyph">•</span>25-hydroxyvitamin D</p><p class="bulletIndent2"><span class="glyph">•</span>Alkaline phosphatase</p><p></p><p class="bulletIndent1">In those patients with eGFR ≥30 mL/min/1.73 m<sup>2</sup> who have normal initial biochemical tests, indicating the absence of coexisting CKD-MBD, we make the diagnosis of osteoporosis as in patients without CKD. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"</a>.)</p><p></p><p class="bulletIndent1">In patients with eGFR ≥30 but &lt;60 mL/min/1.73 m<sup>2</sup> (ie, G3a and G3b) who have abnormalities on initial testing suggestive of CKD-MBD (eg, secondary hyperparathyroidism, hyperphosphatemia), management and monitoring of secondary hyperparathyroidism and mineral metabolism abnormalities, prior to consideration of osteoporosis therapy, is necessary. (See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Defining vitamin D sufficiency'</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>eGFR &lt;30 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – For patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> with a history of a fragility fracture and/or low BMD (DXA T-score ≤-2.5), we measure:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bone-specific alkaline phosphatase (BSAP)</p><p class="bulletIndent2"><span class="glyph">•</span>Calcium</p><p class="bulletIndent2"><span class="glyph">•</span>Phosphorus</p><p class="bulletIndent2"><span class="glyph">•</span>PTH</p><p class="bulletIndent2"><span class="glyph">•</span>25-hydroxyvitamin D</p><p></p><p class="bulletIndent1">Measurement of PTH and BSAP may be used to predict underlying bone turnover and can be helpful in excluding the presence of adynamic bone disease [<a href="#rid29">29,56,57</a>]. (See <a class="local">'Parathyroid hormone'</a> below and <a class="local">'Bone-specific alkaline phosphatase'</a> below.)</p><p></p><p class="bulletIndent1">However, bone biopsy is the gold standard for establishing the type of renal bone disease since no combination of biochemical parameters is sufficiently accurate. Indications for bone biopsy are reviewed briefly below and elsewhere. (See <a class="local">'Bone biopsy'</a> below and  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy", section on 'Bone biopsy for selected patients'</a>.)</p><p></p><p class="bulletIndent1">Measurement of 1,25-dihydroxyvitamin D is not recommended, because the values are not stable, the assay is expensive, and the serum does not reflect tissue levels.</p><p></p><p class="headingAnchor" id="H931377"><span class="h2">Interpretation of lab tests</span></p><p class="headingAnchor" id="H2671329"><span class="h3">Calcium, phosphorus, vitamin D</span><span class="headingEndMark"> — </span>In the majority of patients, serum calcium and phosphorus typically remain normal until glomerular filtration rate (GFR) declines below 25 to 40 mL/min/1.73 m<sup>2</sup> [<a href="#rid58">58</a>]. In patients with more severe CKD, hypercalcemia may signal the possibility of adynamic bone disease. However, other causes of hypercalcemia (eg, hyperparathyroidism, multiple myeloma) should be considered. The rise in plasma calcium in patients with adynamic bone disease is due, in part, to a marked reduction in the bone uptake of calcium after a calcium load (eg, <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> to treat hyperphosphatemia). (See  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p>25-hydroxyvitamin D deficiency is a common finding in predialysis patients with CKD and is associated with elevated PTH levels, which may worsen the manifestations of secondary hyperparathyroidism in this setting (see  <a class="medical medical_review" href="/z/d/html/2048.html" rel="external">"Causes of vitamin D deficiency and resistance", section on 'Chronic kidney disease'</a>). </p><p>Calcitriol (1,25-dihydroxyvitamin D), the most active metabolite of vitamin D, is principally synthesized in the kidney. Circulating calcitriol levels begin to fall when the GFR is less than 40 mL/min/1.73 m<sup>2</sup> and are typically markedly reduced in patients with end-stage kidney disease [<a href="#rid58">58</a>]. In addition to the loss of functioning renal mass, calcitriol production is also reduced by phosphate retention and elevated levels of fibroblast growth factor 23 (FGF23).</p><p class="headingAnchor" id="H2671336"><span class="h3">Parathyroid hormone</span><span class="headingEndMark"> — </span>PTH levels are used as a surrogate to identify the extremes of bone turnover. A serum intact PTH (1-84) that is nine times (eg, 585 pg/mL) or more above the upper limit of the normal range is usually associated with histomorphometric features of osteitis fibrosa cystica, eg, severe parathyroid bone disease [<a href="#rid2">2,49</a>]. Very low PTH levels (&lt;100 pg/mL) are usually associated with adynamic bone disease [<a href="#rid2">2</a>]. If PTH levels are modestly elevated (eg, &gt;150 pg/mL), they are not predictive of underlying bone disease [<a href="#rid59">59,60</a>].</p><p>In a cross-sectional study evaluating the ability of serum intact PTH to predict bone turnover in 492 dialysis patients who had bone histomorphometric assessment of bone turnover, a PTH of &gt;323 pg/mL best discriminated high from non-high bone turnover [<a href="#rid57">57</a>]. A PTH level of &lt;103.8 pg/mL best discriminated low from non-low turnover. However, the discriminatory ability of a single level to predict bone turnover was suboptimal (area under the receiver operator curve [AUROC] &lt;0.8) [<a href="#rid57">57</a>]. Nevertheless, in the absence of bone biopsy, PTH levels are the best available parameter to identify the extremes of bone turnover. The ability of serum PTH to predict adynamic bone disease is predicated on the basis that the PTH synthesis is not being blunted by any pharmacologic agent (eg, vitamin D analogues, or <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a>).</p><p>KDIGO (Kidney Disease Improving Global Outcomes) suggests using PTH trends rather than absolute targets to guide treatment decisions, although this strategy has not been tested specifically for distinguish osteoporosis from other elements of CKD-MBD, including renal osteodystrophy [<a href="#rid29">29,57</a>].</p><p>An important consideration in interpreting PTH levels in CKD is not to assume that an elevated PTH in a patient with CKD means that the increased PTH is due only to CKD. It is important to have a broad perspective on other causes of secondary hyperparathyroidism  (<a class="graphic graphic_table graphicRef73157" href="/z/d/graphic/73157.html" rel="external">table 5</a>) such that the finding of an elevated PTH and a reduced eGFR does not automatically imply that the two are linked [<a href="#rid61">61</a>]. Many conditions associated with osteoporosis may have correctable causes of elevated PTH levels even when discovered at the same time as CKD.</p><p class="headingAnchor" id="H2671343"><span class="h3">Bone-specific alkaline phosphatase</span><span class="headingEndMark"> — </span>Although biochemical markers of bone turnover cannot be used to diagnose osteoporosis, these markers may provide support that one or another form of renal bone disease may be present, and they are valuable for assessing systemic rates of bone turnover [<a href="#rid62">62-67</a>]. In clinical practice, the marker that has the most value in discriminating bone turnover in CKD is BSAP [<a href="#rid56">56,68</a>]. In particular, a high BSAP may be helpful in excluding the presence of adynamic bone disease. In a cross-sectional study evaluating the ability of serum BSAP to predict bone turnover in 492 dialysis patients who had bone histomorphometric assessment of bone turnover, a BSAP level of &lt;33.1 Unit/L (in an assay with reference range 11.6 to 42.7 Unit/L) best discriminated low from non-low bone turnover (AUROC 0.76) [<a href="#rid57">57</a>]. Thus, in this assay, a serum BSAP above 33.1 Unit/L probably excludes adynamic bone disease. A BSAP of &gt;42.1 Unit/L best discriminated high from non-high bone turnover (AUROC 0.71). The combination of intact PTH and BSAP was slightly better able to discriminate bone turnover than BSAP alone.</p><p>The BSAP threshold that best discriminates low bone turnover (adynamic bone disease) will vary with the assay employed. However, a serum BSAP above the upper limit of the laboratory reference range is rarely, if ever, seen in patients with adynamic bone disease unless there has been a recent fracture. Bone cellular activity is reduced in adynamic bone disease, and BSAP is derived from osteoblast activity. While an elevated BSAP provides biochemical evidence that adynamic bone disease is unlikely, the cause of the elevated BSAP requires further evaluation  (<a class="graphic graphic_table graphicRef87761" href="/z/d/graphic/87761.html" rel="external">table 6</a>).</p><p>Other markers of bone turnover used in the assessment and management of osteoporosis are not useful in the assessment and management of CKD-MBD. That is because the preferred biochemical marker of bone resorption, serum C-telopeptide (CTX), and the preferred markers of bone formation, monomeric forms of serum propeptide type I collagen (PINP), are both cleared by the kidney [<a href="#rid62">62,64,66,67</a>]. The only available biochemical markers that are not cleared by the kidney are BSAP, tartrate resistant acid phosphatase (TRAP5b, an osteoclast cellular marker), and the trimer form of PINP  (<a class="graphic graphic_table graphicRef87760" href="/z/d/graphic/87760.html" rel="external">table 7</a>) [<a href="#rid64">64,69</a>]. These markers may provide better discriminatory data on turnover than those that are cleared by the kidney and may have value in fracture prediction in pre-dialysis CKD [<a href="#rid50">50,63,64,69</a>].</p><p class="headingAnchor" id="H931384"><span class="h2">Bone biopsy</span><span class="headingEndMark"> — </span>Because it is invasive and requires special equipment and a great deal of expertise, most clinicians do not perform bone biopsies outside clinical research. Bone biopsy should be performed at the discretion of the metabolic bone disease specialist, if an expert skilled in the performance and interpretation of the technique is available. Bone biopsy is particularly important in patients for whom a specific diagnosis of bone disease has significant management implications. In particular, in clinical settings where a management decision (eg, whether to recommend an antiresorptive osteoporosis therapy) must exclude adynamic bone disease and biochemical testing is not helpful in differentiating among the bone disorders, bone biopsy should be performed.</p><p>Transiliac bone biopsy is the most reliable test for diagnosing the various forms of renal osteodystrophy (osteomalacia, hyperparathyroid, or adynamic renal bone disease) in patients with CKD [<a href="#rid70">70-72</a>]. Each of these forms of renal bone disease has specific quantitative histomorphometric criteria and management strategies [<a href="#rid40">40,41,50,51</a>]. The presence of renal osteodystrophy suggests more complex physiological abnormalities, and the traditional pharmacologic agents used in osteoporosis may not be effective or safe. (See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a> and  <a class="medical medical_review" href="/z/d/html/114322.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Management", section on 'Candidates for pharmacologic treatment'</a>.)</p><p>There are no established criteria for the diagnosis of osteoporosis by quantitative bone histomorphometry. While osteoporosis, especially the most prevalent form, postmenopausal osteoporosis, has by definition a low bone volume, there may be a range of bone turnover from low to high in the osteoporotic population. Abnormalities in bone microarchitecture or quality may increase fragility even if the bone mass in normal. The absence of an office-based tool for measuring bone quality is a major limitation in the assessment of skeletal health.</p><p class="headingAnchor" id="H1216395"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of fragility fracture and/or low bone mineral density (BMD) in patients with chronic kidney disease (CKD) includes the spectrum of mineral and bone disorders of CKD-MBD (mineral and bone disorder). (See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a> and  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p>Patients with kidney disease could also have fractures due to malignancies with metastases, myeloma and marrow diseases, or infections such as tuberculosis.</p><p class="headingAnchor" id="H809749753"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a>.)</p><p class="headingAnchor" id="H301271"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15405.html" rel="external">"Patient education: Chronic kidney disease (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics (see  <a class="medical medical_patient" href="/z/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4410.html" rel="external">"Patient education: Chronic kidney disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H931427"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions – </strong>Changes in mineral metabolism and bone structure develop early in the course of chronic kidney disease (CKD) and worsen with progressive loss of kidney function. CKD-MBD (mineral and bone disorder) includes abnormalities of calcium, phosphorus, parathyroid hormone (PTH), and/or vitamin D; abnormalities in bone turnover, mineralization, volume, linear growth, or strength; and/or vascular or other soft tissue calcification. (See <a class="local">'CKD-MBD definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnitude of the problem – </strong>Both moderate and end-stage CKD are associated with an increased risk of fragility (low trauma) fractures. The exact mechanism for this greater fracture risk in CKD is not clearly established, but there are biological changes in bone metabolism that render the skeleton in patients with progressive CKD (glomerular filtration rate [GFR] stages G3 to G5  (<a class="graphic graphic_table graphicRef70597" href="/z/d/graphic/70597.html" rel="external">table 2</a>)) more fragile. (See <a class="local">'Magnitude of the problem'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of fracture risk</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FRAX</strong> – In clinical practice, a Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=13914" target="_blank">FRAX</a>) may be applied to CKD patients with adjustment of the absolute fracture risk to a higher level in patients with estimated glomerular filtration rate (eGFR) stages G3b to G5  (<a class="graphic graphic_table graphicRef70597" href="/z/d/graphic/70597.html" rel="external">table 2</a>). (See <a class="local">'Fracture risk assessment tool'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone mineral density: DXA</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CKD and eGFR ≥30 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – For patients with CKD, eGFR ≥30 mL/min/1.73 m<sup>2</sup>, and risk factors for fracture, bone mineral density (BMD) (dual-energy x-ray absorptiometry [DXA]) testing may be used to assess fracture risk. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>eGFR &lt;30 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – Although BMD testing is not routinely performed to assess fracture risk in patients with CKD and eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, it may be obtained in selected patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup> who have fragility fracture and no evidence of CKD-MBD, including renal osteodystrophy, particularly when osteoporosis therapy is being considered. (See <a class="local">'Bone mineral density: DXA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of osteoporosis in CKD</strong> –<strong> </strong>It is difficult to diagnose osteoporosis in the setting of CKD-MBD. Patients with CKD may have osteoporosis either before or after developing kidney disease. Osteoporosis, a term that includes major alterations in bone quality, is probably a universal feature accompanying bone disease in all forms of renal bone disease  (<a class="graphic graphic_table graphicRef115571" href="/z/d/graphic/115571.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>eGFR ≥30 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – In patients with CKD and eGFR ≥30 mL/min/1.73 m<sup>2</sup>, we use the World Health Organization (WHO) criteria (BMD T-score 2.5 standard deviations or more below the young adult mean BMD) or the presence of a fragility fracture to make the diagnosis of osteoporosis, assuming that there are no accompanying biochemical abnormalities (hyperparathyroidism, hyperphosphatemia) that indicate the coexistence of renal osteodystrophy or CKD-MBD  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>eGFR &lt;30 mL/min/1.73 m</strong><strong><sup>2</sup></strong> – In patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, who have low BMD T-scores or history of fragility fracture, bone physiology is more complex, and features of CKD-MBD may predominate. In this setting, a diagnosis of osteoporosis can only be made by excluding CKD-MBD, including renal osteodystrophy, with laboratory tests and sometimes a bone biopsy  (<a class="graphic graphic_table graphicRef115571" href="/z/d/graphic/115571.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory assessment</strong> – For patients with eGFR ≥30 but &lt;60 mL/min/1.73 m<sup>2</sup> and a history of a fragility fracture and/or low BMD (DXA T-score ≤-2.5), we initially measure serum calcium, phosphorus, PTH, 25-hydroxyvitamin D, and alkaline phosphatase. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2">For similar patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, we also measure bone specific alkaline phosphatase (BSAP). Along with PTH, BSAP may have value in differentiating among the various forms of renal osteodystrophy. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of bone biopsy</strong> –<strong> </strong>Because it is invasive and requires special equipment and a great deal of expertise, most clinicians do not perform bone biopsies outside clinical research. Bone biopsy should be performed at the discretion of the metabolic bone disease specialist, if an expert skilled in the performance and interpretation of the technique is available. Bone biopsy is particularly important in patients for whom a specific diagnosis of bone disease has significant management implications. (See <a class="local">'Bone biopsy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17:505S.</a></li><li><a class="nounderline abstract_t">Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.</a></li><li><a class="nounderline abstract_t">Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36:1115.</a></li><li><a class="nounderline abstract_t">Danese MD, Kim J, Doan QV, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47:149.</a></li><li><a class="nounderline abstract_t">Kim SM, Long J, Montez-Rath M, et al. Hip Fracture in Patients With Non-Dialysis-Requiring Chronic Kidney Disease. J Bone Miner Res 2016; 31:1803.</a></li><li><a class="nounderline abstract_t">Nitsch D, Mylne A, Roderick PJ, et al. Chronic kidney disease and hip fracture-related mortality in older people in the UK. Nephrol Dial Transplant 2009; 24:1539.</a></li><li><a class="nounderline abstract_t">Jamal SA, West SL, Miller PD. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2012; 23:1191.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167:133.</a></li><li><a class="nounderline abstract_t">Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17:3223.</a></li><li><a class="nounderline abstract_t">Dukas L, Schacht E, Stähelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of &lt;65 ml/min is a risk factor for falls and fractures. Osteoporos Int 2005; 16:1683.</a></li><li><a class="nounderline abstract_t">Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 2007; 18:282.</a></li><li><a class="nounderline abstract_t">Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis 2008; 51:38.</a></li><li><a class="nounderline abstract_t">Naylor KL, McArthur E, Leslie WD, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int 2014; 86:810.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Parimi N, Fink HA, et al. Estimated GFR and risk of hip fracture in older men: comparison of associations using cystatin C and creatinine. Am J Kidney Dis 2014; 63:31.</a></li><li><a class="nounderline abstract_t">LaCroix AZ, Lee JS, Wu L, et al. Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women. J Am Geriatr Soc 2008; 56:1434.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Barbour K, Canales MT, et al. Renal function and nonvertebral fracture risk in multiethnic women: the Women's Health Initiative (WHI). Osteoporos Int 2012; 23:887.</a></li><li><a class="nounderline abstract_t">Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res 2007; 22:203.</a></li><li><a class="nounderline abstract_t">Vilaca T, Salam S, Schini M, et al. Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis. Am J Kidney Dis 2020; 76:521.</a></li><li><a class="nounderline abstract_t">Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012; 8:276.</a></li><li><a class="nounderline abstract_t">Hruska KA, Mathew S. The roles of the skeleton and phosphorus in the CKD mineral bone disorder. Adv Chronic Kidney Dis 2011; 18:98.</a></li><li><a class="nounderline abstract_t">Jüppner H. Phosphate and FGF-23. Kidney Int Suppl 2011; :S24.</a></li><li><a class="nounderline abstract_t">Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8:819.</a></li><li class="breakAll">National Osteoporosis Foundation. Osteoporosis and chronic kidney disease updates, 2010 http://www.nof.org/sites/default/files/clinicalupdates/Issue20KidneyDisease/kidney.html (Accessed on September 25, 2012).</li><li><a class="nounderline abstract_t">Naylor KL, Garg AX, Zou G, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 2015; 10:646.</a></li><li><a class="nounderline abstract_t">Whitlock RH, Leslie WD, Shaw J, et al. The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney Int 2019; 95:447.</a></li><li class="breakAll">Miller PD, Jamal S, West S. Bone mineral density in chronic kidney disease-use and misuse. Clin Rev Bone and Mineral Metab 2012; 10:163. http://www.springerlink.com/content/0364267gmnm85147/ (Accessed on September 25, 2012).</li><li><a class="nounderline abstract_t">Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011; 22:2395.</a></li><li><a class="nounderline abstract_t">Jamal SA, West SL, Nickolas TL. The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 2014; 25:71.</a></li><li class="breakAll">KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) http://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf (Accessed on November 08, 2017).</li><li><a class="nounderline abstract_t">Evenepoel P, Cunningham J, Ferrari S, et al. Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int 2021; 32:2397.</a></li><li><a class="nounderline abstract_t">Yenchek RH, Ix JH, Shlipak MG, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012; 7:1130.</a></li><li><a class="nounderline abstract_t">Bucur RC, Panjwani DD, Turner L, et al. Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis. Osteoporos Int 2015; 26:449.</a></li><li><a class="nounderline abstract_t">West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 2015; 30:913.</a></li><li><a class="nounderline abstract_t">Nickolas TL, Stein E, Cohen A, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 2010; 21:1371.</a></li><li><a class="nounderline abstract_t">Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49:674.</a></li><li><a class="nounderline abstract_t">Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Nephrol Dial Transplant 2012; 27:345.</a></li><li><a class="nounderline abstract_t">Ott SM. Review article: Bone density in patients with chronic kidney disease stages 4-5. Nephrology (Carlton) 2009; 14:395.</a></li><li><a class="nounderline abstract_t">Ersoy FF, Passadakis SP, Tam P, et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 2006; 24:79.</a></li><li><a class="nounderline abstract_t">Jamal SA, Chase C, Goh YI, et al. Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 2002; 39:843.</a></li><li><a class="nounderline abstract_t">Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2:595.</a></li><li><a class="nounderline abstract_t">Lehmann G, Ott U, Kaemmerer D, et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 - 5. Clin Nephrol 2008; 70:296.</a></li><li><a class="nounderline abstract_t">Wehrli FW, Leonard MB, Saha PK, Gomberg BR. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imaging 2004; 20:83.</a></li><li><a class="nounderline abstract_t">Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Semin Dial 2007; 20:423.</a></li><li><a class="nounderline abstract_t">Miller PD. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009; 29:144.</a></li><li class="breakAll">World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva 1994. http://whqlibdoc.who.int/trs/WHO_TRS_843.pdf (Accessed on October 03, 2012).</li><li><a class="nounderline abstract_t">Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185.</a></li><li><a class="nounderline abstract_t">Coen G. Adynamic bone disease: an update and overview. J Nephrol 2005; 18:117.</a></li><li><a class="nounderline abstract_t">Miller PD. Chronic kidney disease and the skeleton. Bone Res 2014; 2:14044.</a></li><li><a class="nounderline abstract_t">Barreto FC, Barreto DV, Moyses RM, et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 2006; 69:1852.</a></li><li><a class="nounderline abstract_t">Ferreira MA. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrol Dial Transplant 2000; 15 Suppl 5:8.</a></li><li><a class="nounderline abstract_t">Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73:1345.</a></li><li><a class="nounderline abstract_t">Hruska KA, Mathew S, Lund RJ, et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol 2009; 29:156.</a></li><li><a class="nounderline abstract_t">London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15:1943.</a></li><li><a class="nounderline abstract_t">Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012; 8:529.</a></li><li><a class="nounderline abstract_t">Tomiyama C, Carvalho AB, Higa A, et al. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res 2010; 25:499.</a></li><li><a class="nounderline abstract_t">Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol 2013; 8:299.</a></li><li><a class="nounderline abstract_t">Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 2016; 67:559.</a></li><li><a class="nounderline abstract_t">Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31.</a></li><li><a class="nounderline abstract_t">Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63:284.</a></li><li><a class="nounderline abstract_t">Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43:558.</a></li><li><a class="nounderline abstract_t">Miller PD. Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 2012; 41:613.</a></li><li><a class="nounderline abstract_t">Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009; 20:843.</a></li><li class="breakAll">Miller PD, Shane E. Management of transplantation renal bone disease: Interplay of bone mineral density and decisions regarding bisphosphonate use. In: Medical Management of Kidney Transplantation, Weir MR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.359.</li><li><a class="nounderline abstract_t">Nickolas TL, Cremers S, Zhang A, et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 2011; 22:1560.</a></li><li><a class="nounderline abstract_t">Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24:561.</a></li><li><a class="nounderline abstract_t">Bauer D, Krege J, Lane N, et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012; 23:2425.</a></li><li><a class="nounderline abstract_t">Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22:391.</a></li><li><a class="nounderline abstract_t">Delanaye P, Souberbielle JC, Lafage-Proust MH, et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant 2014; 29:997.</a></li><li><a class="nounderline abstract_t">Leeming DJ, Alexandersen P, Karsdal MA, et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006; 62:781.</a></li><li><a class="nounderline abstract_t">Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008; 3 Suppl 3:S140.</a></li><li class="breakAll">Miller PD. Renal bone diseases. In: Atlas of Metabolic Bone Diseases, 3rd, Orwoll E (Ed), Springer, New York 2008. p.135.</li><li><a class="nounderline abstract_t">Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26:1368.</a></li></ol></div><div id="topicVersionRevision">Topic 13914 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8573428" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The worldwide problem of osteoporosis: insights afforded by epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16641930" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096034" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377396" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27145189" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hip Fracture in Patients With Non-Dialysis-Requiring Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075194" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronic kidney disease and hip fracture-related mortality in older people in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21901475" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fracture risk assessment in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242313" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal function and risk of hip and vertebral fractures in older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005938" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Relationship between moderate to severe kidney disease and hip fracture in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15933802" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In elderly men and women treated for osteoporosis a low creatinine clearance of&lt;65 ml/min is a risk factor for falls and fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17167115" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of kidney function with incident hip fracture in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18155531" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Increased risk of hip fracture among men with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24429401" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The three-year incidence of fracture in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23890927" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Estimated GFR and risk of hip fracture in older men: comparison of associations using cystatin C and creatinine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18662213" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21625880" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Renal function and nonvertebral fracture risk in multiethnic women: the Women's Health Initiative (WHI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059370" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654892" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249518" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406294" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The roles of the skeleton and phosphorus in the CKD mineral bone disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346724" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phosphate and FGF-23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430206" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The relation between renal function and serum sclerostin in adult patients with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430206" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The relation between renal function and serum sclerostin in adult patients with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25655423" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of fracture risk prediction among individuals with reduced and normal kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30579724" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30579724" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21779818" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Interpretation and use of FRAX in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114399" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114399" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34129059" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516286" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bone mineral density and fracture risk in older individuals with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25477230" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25400209" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bone mineral density predicts fractures in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395370" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone mass and microarchitecture in CKD patients with fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472850" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21652550" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563381" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Review article: Bone density in patients with chronic kidney disease stages 4-5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369903" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920352" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3455637" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18826854" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 - 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221812" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897249" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Osteoporosis and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371805" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnosis and treatment of osteoporosis in chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371805" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Diagnosis and treatment of osteoporosis in chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940371" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Predictive value of BMD for hip and other fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15931639" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adynamic bone disease: an update and overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26273531" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chronic kidney disease and the skeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16612334" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073268" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337716" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adynamic bone in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371806" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213285" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Arterial calcifications and bone histomorphometry in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473330" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Arterial calcification and bone physiology: role of the bone-vascular axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19594321" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22403273" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : PTH--a particularly tricky hormone: why measure it at all in kidney patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321176" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17091124" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15847255" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981615" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22877432" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Unrecognized and unappreciated secondary causes of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190842" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bone turnover markers: understanding their value in clinical trials and clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190842" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bone turnover markers: understanding their value in clinical trials and clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784896" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Discriminants of prevalent fractures in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19257812" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797491" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21184054" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23868144" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912870" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988699" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The role of bone biopsy in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988699" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The role of bone biopsy in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21611975" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
